Catalio Capital Management, LP 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Catalio Capital Management, LP disclosed 41 US equity positions worth $478.7m in its Q1 2026 13F filing. The largest position was DNTH at 9.8% of the reported book, followed by BBIO and ASND.
What did Catalio Capital Management, LP own in Q1 2026? Top 41 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 9.8% | $47.0m | 560,308 | – | |
| 2 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 6.7% | $32.1m | 432,014 | – | |
| 3 | ASND ASCENDIS PHARMA A/S | Healthcare | 6.2% | $29.5m | 129,111 | – | |
| 4 | BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 5.3% | $25.5m | 420,727 | – | |
| 5 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 5.1% | $24.4m | 1,043,670 | – | |
| 6 | GILD GILEAD SCIENCES INC | Healthcare | 4.8% | $22.8m | 163,905 | – | |
| 7 | 430 TERNS PHARMACEUTICALS INC | 4.5% | $21.6m | 409,031 | – | ||
| 8 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 4.1% | $19.6m | 1,037,984 | – | |
| 9 | SLNOEUR SOLENO THERAPEUTICS INC | 4.0% | $19.3m | 577,808 | – | ||
| 10 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 3.9% | $18.8m | 299,318 | – | |
| 11 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 3.7% | $17.8m | 850,797 | – | |
| 12 | INCY INCYTE CORP | Healthcare | 3.6% | $17.1m | 182,101 | – | |
| 13 | CYTK CYTOKINETICS INC | Healthcare | 3.0% | $14.2m | 215,501 | – | |
| 14 | NTRA NATERA INC | Healthcare | 3.0% | $14.2m | 70,907 | – | |
| 15 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 2.7% | $13.0m | 891,933 | – | |
| 16 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 2.6% | $12.3m | 255,379 | – | |
| 17 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 2.5% | $11.9m | 439,041 | – | |
| 18 | EW EDWARDS LIFESCIENCES CORP | Healthcare | 2.4% | $11.6m | 144,607 | – | |
| 19 | MANE VERADERMICS INC | Healthcare | 2.3% | $11.0m | 173,582 | – | |
| 20 | ADPT ADAPTIVE BIOTECHNOLOGIES COR | Healthcare | 2.1% | $10.0m | 722,784 | – | |
| 21 | HTFL HEARTFLOW INC | Healthcare | 2.1% | $9.8m | 403,588 | – | |
| 22 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.8% | $8.6m | 426,551 | – | ||
| 23 | UNIQURE NV | 1.7% | $8.0m | 491,116 | – | ||
| 24 | IRON DISC MEDICINE INC | Healthcare | 1.6% | $7.9m | 122,978 | – | |
| 25 | SEPN SEPTERNA INC | Healthcare | 1.5% | $7.1m | 294,360 | – | |
| 26 | ABVX ABIVAX SA | Healthcare | 1.1% | $5.3m | 47,193 | – | |
| 27 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.1% | $5.1m | 282,954 | – | |
| 28 | ELDN ELEDON PHARMACEUTICALS INC | 1.1% | $5.1m | 1,639,816 | – | ||
| 29 | KPTI KARYOPHARM THERAPEUTICS INC | 1.0% | $5.0m | 897,709 | – | ||
| 30 | SUPN SUPERNUS PHARMACEUTICALS | Healthcare | 0.7% | $3.2m | 62,019 | – | |
| 31 | TARA PROTARA THERAPEUTICS INC | 0.6% | $3.0m | 580,024 | – | ||
| 32 | PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 0.6% | $2.8m | 247,767 | – | |
| 33 | NEWAMSTERDAM PHARMA COMPANY | 0.6% | $2.7m | 83,554 | – | ||
| 34 | TYRA TYRA BIOSCIENCES INC | Healthcare | 0.5% | $2.6m | 67,285 | – | |
| 35 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 0.5% | $2.5m | 84,352 | – | |
| 36 | GUTS FRACTYL HEALTH INC | 0.5% | $2.5m | 5,491,866 | – | ||
| 37 | HYPR HYPERFINE INC | 0.3% | $1.4m | 1,320,041 | – | ||
| 38 | MGX METAGENOMI THERAPEUTICS INC | 0.1% | $708.9k | 528,993 | – | ||
| 39 | ATAI ATAIBECKLEY INC | 0.1% | $696.9k | 196,858 | – | ||
| 40 | FTH SENSEI BIOTHERAPEUTICS INC | 0.1% | $463.9k | 14,718 | – | ||
| 41 | OM OUTSET MED INC | 0.1% | $454.2k | 118,279 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.